Salvage lenvatinib/everolimus (LE) combination therapy after immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) for metastatic renal cell carcinoma (mRCC) von Khorasanchi, Adam, Kwok, Christopher, Psutka, Sarah P., Hinkley, Megan, Dason, Shawn, Yang, Yuanquan (Aaron), Verschraegen, Claire F., Gross, Evan, Orcutt, Delaney, Yin, Ming

Volltext

Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alt... von Jain, Rohit K., Heiligh, Jazlyn, Kim, Youngchul, Piekarz, Richard, Pelosof, Lorraine Cheryl, Yang, Yuanquan (Aaron), D'souza, Anishka, Wong, Risa Liang, Graham, Laura, Gupta, Sumati, Park, Anna, Synold, Timothy W., Sonpavde, Guru P.

Volltext

Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma von Jain, Rohit K., Yang, Yuanquan (Aaron), Chadha, Juskaran, Zhang, Jingsong, Raymond, Sarah, Oschmann, Erika, Poehlman, Trey, Fan, Wenyi, Kim, Youngchul, Dhillon, Jasreman, Chahoud, Jad, Chatwal, Monica Sheila, Sonpavde, Guru P.

Volltext

Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587) von Serzan, Michael Thomas, Jegede, Opeyemi, Bilen, Mehmet Asim, Braun, David A., Einstein, David Johnson, Haas, Naomi B., Hammers, Hans J., King, Jennifer, Runcie, Karie, Sosman, Jeffrey A., Sternberg, Cora N., Yang, Yuanquan (Aaron), Choueiri, Toni K., Signoretti, Sabina, Atkins, Michael B.

Volltext